

The Prostate Cancer Foundation (PCF) & Pfizer Inc. announce
PCF-Pfizer Global Challenge Awards

Request for Proposals (RFP)
September 26, 2019

About the Prostate Cancer Foundation

The Prostate Cancer Foundation (PCF) is the world's leading philanthropic organization dedicated to funding life-saving prostate cancer research. Founded in 1993, PCF has raised nearly \$800 million to support cutting-edge research by 2,200 scientists at 220 leading cancer centers in 22 countries around the world. Nearly every FDA-approved treatment for prostate cancer since 2004 was seeded and supported by PCF. The overall scientific goal of PCF is to cure prostate cancer. Learn more at pcf.org.

About Pfizer Global Medical Grants

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies. Pfizer's GMG competitive grant program involves a publicly posted RFP that provides detail regarding a specific area of interest, sets timelines for review and approval, and works with a partner organization or an external review panel to make final grant decisions. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program.

Competitive Research Grant Program Eligibility

Geographic Scope	Global, institutions in all countries and geographic regions are eligible to apply
PCF-Pfizer Challenge Award Team Eligibility Criteria	<p>To be eligible:</p> <ul style="list-style-type: none"> Composed of a team of at least three (3) investigators from non-profit academic research centers, including one young investigator. Applicants (Principle Investigator; PI) must have a medical or postdoctoral degree (MD, PhD, or equivalent)

- The young investigator may hold the title of Postdoctoral Fellow, Instructor, Research Associate, Assistant Professor, or equivalent and should be within six-years following completion of a professional degree (MD, DO, PhD, MD-PhD, DSc, ScD, DDM, DDS, DMD, MBBS, or equivalent) or subsequent mentored academic or clinical training program.
- Both early career and experienced investigators are encouraged to apply, and consideration will be given to all proposals meeting the selection criteria

Requirements

Clinical Area	Oncology – Genitourinary – Prostate Cancer
Area of Interest / Research Focus	<p>The intent of this RFP is to invite investigators from across the globe to submit innovative proposals for clinical investigations with correlative research for talazoparib in prostate cancer.</p> <p>Research proposals in the following topic areas are preferred:</p> <ul style="list-style-type: none"> • Talazoparib in early and advanced stages of prostate cancer • Talazoparib in molecularly-unselected patient populations, as appropriate • Combination of talazoparib with novel agents • Talazoparib in combination with next-generation androgen axis-targeted therapies (other than enzalutamide) • Talazoparib in combination with PSMA radiotherapeutics • Identifying resistance mechanisms to talazoparib with treatment strategies to avoid or overcome resistance <p>General guidance to all proposals:</p> <ul style="list-style-type: none"> • Please include plan for increasing diversity in clinical study enrollment • All studies should include comprehensive translational oncology analyses, including correlation of outcomes with DNA Damage Repair (DDR) gene mutation status • For combination with non-Pfizer assets, applicants may simultaneously apply for drug-only from other companies

<p>Expected Approximate Monetary Range of Grant Applications</p>	<ul style="list-style-type: none"> • Approximately \$2 million USD are allocated to this research grants program • Applications will be reviewed by an independent review panel. It is expected that 2-3 clinical studies will be selected for funding. • The amount of the grant for any project will depend upon the external review panel's evaluation of the proposal's budget and costs involved, and will be stated clearly in the approval notification
<p>Key Dates</p>	<ul style="list-style-type: none"> • RFP release date: September 26, 2019 • Letter of Intent (LOI) due date: December 3, 2019 <p><i>Please note the deadline is midnight Eastern Time (New York, GMT -5).</i></p> <ul style="list-style-type: none"> • Anticipated LOI Notification Date: January 21, 2020 • Full Proposal Deadline: March 23, 2020 • Only accepted LOIs will be invited to submit full proposals <p><i>Please note the deadline is midnight Eastern Time (New York, GMT -5)</i></p> <ul style="list-style-type: none"> • Anticipated Full Proposal Notification Date: May 28, 2020
<p>How to Apply</p>	<p>Please go to www.cybergrants.com/pfizer/loi and sign in. First-time users should click "REGISTER NOW".</p> <p>Requirements for submission:</p> <ul style="list-style-type: none"> • Select the following Competitive Grant Program Name: 2019 Oncology G - PCF-Pfizer Global Challenge Awards • Complete all required sections of the online application. See Appendix A for additional details • If you encounter any technical difficulties with the website, please click the "Technical Questions" link at the bottom of the page
<p>Questions:</p>	<ul style="list-style-type: none"> • If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Jacqueline Waldrop (Jacqueline.Waldrop@pfizer.com), with the subject line "PCF-Pfizer Global Challenge Awards" • Please click here to view Frequently Asked Questions regarding the Competitive Grant Program
<p>Mechanism by which Applicants will be Notified:</p>	<ul style="list-style-type: none"> • All applicants will be notified via email by the dates noted above • Applicants may be asked for additional clarification during the review period

Appendix A

Letter of Intent Requirements

The Letter of Intent (LOI) will be accepted via the online application. When answering the LOI questions in the application please keep the following in mind:

Goals and Objectives	Provide the main goal of the study and the study population. Provide a detailed definition that is directly linked to the primary objective
Assessment of Need for the Project	This should reflect your study rationale. Provide a brief description of the medical question and the rationale of how this project addresses the question
Patient Population/Target Audience	Describe the target patient population. For Investigator Sponsored Trials, please specify the age and other demographic information for trial population Also indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the sample size calculation of your study population.
Project Design and Methods	Describe concisely the research design and methods for achieving the stated goals. For a clinical interventional study; include inclusion/exclusion criteria, treatment plan, statistical plan and correlative analyses.
Innovation	Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project.
Evaluation and Outcomes	Specify type and frequency of safety, efficacy, and outcome measures. Also indicate the method(s) used to assess measures
Anticipated Project Timeline	Provide an anticipated timeline for your project including project start/end dates
Additional Information	If there is any additional information you feel PCF and Pfizer should be aware of concerning the importance of this project, please summarize here
Organization Detail	This information is used to assess the capability of the organizational resources available to perform the effort proposed. Identify the facilities to be used [laboratory, animal, clinical and "other"]. If appropriate, indicate their capacities, pertinent capabilities, relative proximity and extent of availability to the project.